In:
Psychiatry and Clinical Neurosciences, Wiley, Vol. 60, No. 5 ( 2006-10), p. 584-589
Abstract:
Abstract The aim of this study was to assess the therapeutic efficacy of the serotonin norepinephrine reuptake inhibitor (SNRI), milnacipran, on both cognitive impairment and depression in post‐stroke depression (PSD) patients. A total of 18 PSD patients, approximately 3 months after stroke, were divided into two groups, milnacipran and control. A total of 10 patients were assigned to the milnaciprane group and eight were assigned to control group. Their cognitive impairment and mood symptoms were measured using the Mini‐Mental State Examination (MMSE) and Hamilton Depression Rating Scale (HAM‐D) both at the time of admission and at discharge, an interval of approximately 3 months. This study examined the changes in both MMSE and HAM‐D scores during the study period. A significant time‐by‐group interaction for results of the MMSE was observed, although there was no significant difference between the two groups on the HAM‐D. Amelioration of cognitive impairment was greater in the milnacipran group than the control group. For PSD patients, milnacipran is effective in improving cognitive dysfunction.
Type of Medium:
Online Resource
ISSN:
1323-1316
,
1440-1819
DOI:
10.1111/pcn.2006.60.issue-5
DOI:
10.1111/j.1440-1819.2006.01562.x
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
2010264-1
Permalink
